




AZAPROSTANOIDS II. SYNTHESIS OF
12-AZACARBOPROSTACYCLIN ANALOGS¹


Chia-Lin J. Wang
Central Research and Development Department, Experimental Station
E. I. du Pont de Nemours and Company
Wilmington, Delaware 19898


ABSTRACT: A total synthesis of 12-azacarboprostacyclin analogs 1 and 2 from 9 is described.

Synthetic orally active drugs based on prostacyclin² (PGI₂) could be potentially useful in the treatment of thrombotic disease, hypertension, platelet consumption and all forms of vascular disease.³ Tremendous efforts have been focused upon carboprostacyclin⁴ because of its PGI₂-like biological profile.⁵ We have been interested in preparing azacarboprostacyclin analogs as potential anti-thrombotic agents for some time. A recent report⁶ describing the synthesis of 12-azaprostacyclin analogs prompts us to disclose our efforts in this area. In this communication, we wish to report the synthesis of 12-azacarboprostacyclin analogs 1 and 2 from a common intermediate 9.




Retrosynthetically, 1 might be derived from 3 by a Wittig reaction. Compound 3 should be easily synthesized from 4 which, in turn, might be obtained by Dieckmann cyclization of 5 followed by decarboxylation. The readily available 6⁷ could be a suitable starting material for compound 5. The synthesis of 2 was also realized via the common intermediate 9.






The actual synthetic route leading to 1 is shown in Scheme I. Compound 6 was reacted with the phosphonate derived from trimethyl phosphonoacetate to give the α,β -unsaturated ester which was smoothly hydrogenated to the diester 7 as an oil in 70% yield after HPLC purification [IR (neat) 1740, 1700 cm^{-1} ; NMR (CDCl_3) δ 4.17 (q, $J=7\text{Hz}$, $2\text{CO}_2\text{CH}_2\text{CH}_3$), 3.70 (s, CO_2CH_3), 1.27 (t, $J=7\text{Hz}$, $2\text{CO}_2\text{CH}_2\text{CH}_3$)]. Dieckmann cyclization of 7 followed by decarboxylation⁸ gave rise to the oily ketone 8 in 51% yield after purification by HPLC [IR (CH_2Cl_2) 1750, 1700 cm^{-1} ; NMR (CDCl_3) δ 4.11 (q, $J=7\text{Hz}$, $\text{CO}_2\text{CH}_2\text{CH}_3$), 1.23 (t, $J=7\text{Hz}$, $\text{CO}_2\text{CH}_2\text{CH}_3$)]. Ketone 8 was then converted to 9 in 57% yield by the following transformations: 1. protection of the ketone as dimethyl ketal; 2. cleavage of the carbamate by methyl lithium; 3. conjugate addition of the resulting amine to 3-keto-1-heptene and finally, reduction of the ketone. The protected ketone in 9 was unmasked to give 3 as an oil after HPLC purification [IR (CH_2Cl_2) 3250, 1740 cm^{-1}]. Compound 3 was allowed to react with the phosphorane derived from (4-carboxybutyl)-triphenylphosphonium bromide to yield 1⁹ in 85% yield after purification by flash column chromatography using methanol-methylene chloride as an eluent.

Scheme I





Conditions: a. NBS/NaHCO₃/THF-H₂O; b. K₂CO₃/MeOH;
 c. *p*-TsOH/acetone; d. Ph₃P⁺(CH₂)₄CO₂⁻HBr⁻/
 KOBu^t/PhH/80°; e. CH₂N₂

While compound 1 did not inhibit cat platelet aggregation induced by arachidonic acid¹³, compound 2 gave 25% inhibition of ADP-induced rat platelet aggregation at 2.5x10⁻⁴M.¹⁴

References and Notes

1. Contribution No. 3136 from Central Research and Development Department. For Azaprostanoids I. see C.-L. J. Wang, *Tetrahedron Lett.*, **23**, 1067 (1982).
2. S. Moncada, R. Gryglewski, S. Bunting and J.R. Vane, *Nature*, **263**, 663 (1976)
3. J.R. Vane and S. Bergstrom, ed., "Prostacyclin", New York, Raven Press, 1979.
4. For recent publications on the synthesis of carboprostacyclin, see (a) Y. Konishi, M. Kawamura, Y. Iguchi, Y. Arai and M. Hayashi, *Tetrahedron*, **37**, 43 (1981); (b) M. Yamazaki, M. Shibasaki and S. Ikegami, *Chem. Lett.*, 1245 (1981); (c) P.A. Aristoff, *J. Org. Chem.*, **46**, 1954 (1981) and references therein.
5. (a) B.J.R. Whittle, S. Moncada, F. Whiting and J.R. Vane, *Prostaglandins*, 605 (1980); (b) J.W. Aiken, R. J. Shebuski, *ibid*, **19**, 629 (1980).
6. F. Cassidy, R.W. Moore, G. Wootton, K.H. Baggaley, G.R. Geen, L.J.A. Jennings and A.W.R. Tyrrell, *Tetrahedron Lett.*, **22**, 253 (1981).
7. (a) T.A. Geissman and A.C. Waiss, Jr., *J. Org. Chem.*, **27**, 139 (1962); (b) G. Stork and A. G. Schultz, *J. Am. Chem. Soc.*, **93**, 4074 (1971).
8. A.P. Krapcho and A.J. Lovey, *Tetrahedron Lett.*, 957 (1973).
9. 1: oil, IR (CH₂Cl₂) 3400-2600 (br), 1720 cm⁻¹; NMR (CDCl₃) δ 6.50 (bs, 2H, -CO₂H & - OH), 5.11 (m, 1H), 4.20-1.00 (m, 29H), 0.83 (t, 3H); HRMS m/z 337.2611 (M⁺), calcd. for C₂₀H₃₅NO₃: 337.2617.
- 2: oil, consisting of four racemic diastereomers, IR (CH₂Cl₂) 3610-3300 (br), 1740, 1665 cm⁻¹; NMR (CDCl₃) δ 5.20 (m, 1H), 3.63 (s, 3H), 4.10-1.00 (m, 27H), 0.90 (t, 3H); HRMS m/z 365.2559 (M⁺), calcd. for C₂₁H₃₅NO₄: 365.2566.
10. A. Picot and X. Lusinch, *Synthesis*, 109 (1975).
11. In Ref. 6, a closely related five-membered lactam has shown IR absorption at 1670 cm⁻¹.
12. This acid could not be separated from the Wittig reagent.
13. The author thanks Professor A. M. Lefler of Thomas Jefferson University for conducting the tests.
14. I am indebted to Dr. W. Galbraith (Biochemicals Department) for obtaining the data. Technical assistance from Ms. T.L. Taylor is greatly appreciated.